Wedelolactone suppresses breast cancer growth and metastasis via regulating TGF-β1/Smad signaling pathway.

Hui LiManting HouPing ZhangLutong RenYuanyuan GuoLiang ZouJunling CaoZhaofang Bai

Published in: The Journal of pharmacy and pharmacology (2024)

Wed reverses EMT by regulating TGF-β1/Smad pathway, potentially serving as a therapeutic agent for breast cancer. Wed is expected to be a potential drug to inhibit TGF-β1/Smad pathway-related diseases.

Keyphrases

transforming growth factor
epithelial mesenchymal transition
signaling pathway
pi k akt
induced apoptosis
oxidative stress
cell proliferation
human health
childhood cancer